Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis
A. Gordon Smith, MD, FAAN, talks about how new agents and emerging data are enabling clinicians to personalize care for patients with myasthenia gravis.
EP: 1.Prevalence and Pathophysiology of Myasthenia Gravis
EP: 2.Unmet Needs in the Management of Myasthenia Gravis
EP: 3.Standards of Care for Myasthenia Gravis
EP: 4.The Role of Monoclonal Antibodies in the Treatment of Myasthenia Gravis
EP: 5.The Fc Receptor and Mechanisms of Efgartigimod
EP: 6.Clinical Trial Data for Efgartigimod in the Treatment of Myasthenia Gravis
EP: 7.Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis
EP: 8.Determining Treatment Efficacy in the Treatment of Myasthenia Gravis
EP: 9.Investigational Agents for the Treatment of Myasthenia Gravis
EP: 10.Collaborating With Primary Care Physicians for the Management of Patients With Myasthenia Gravis
A. Gordon Smith, MD, FAAN: In the context of these really exciting therapeutic developments and a lot more to come, the treatment of myasthenia gravis is I think, and I hope going to become even more personalized or precision-based. Before it wasn't cookie-cutter, because you would choose therapies based on the clinical scenario, age, comorbidities, and so forth. But increasingly we have agents across multiple- the larger spectrum of therapeutic targets and so we'll continue to treat patients who have diabetes, for instance, separate or differently than those who do not. I'm hopeful in the future that we will have better biomarker evidence or means of trying to determine whether an individual patient would be better treated with B-cell depletion, complement inhibition, FcRn inhibition, corticosteroids, immunosuppressant treatments alone or in combination, and so I really think a lot of the future work in myasthenia gravis therapeutic development is not only going to be exploring new targets and exciting therapies but trying to figure out how we target these therapies to the right patient. I think this is really going to require development of better biomarkers to predict utility of therapeutic approaches.
Transcript edited for clarity
